F+FreeMedSite USMLELearn with clinical reasoning
SEPARATE VIVA EXTENSION

GLP-1 receptor agonists: incretin signaling

Follow-up oral questions and concise, clinically defensible model answers. Your MCQ remains open in its original tab.

← Return to original MCQ
EXAMINER FOLLOW-UP 1

Which enzyme rapidly degrades endogenous GLP-1?

Dipeptidyl peptidase-4 (DPP-4).

EXAMINER FOLLOW-UP 2

What is an important common adverse effect?

Nausea and other gastrointestinal symptoms.

EXAMINER FOLLOW-UP 3

Why is hypoglycemia risk relatively low as monotherapy?

Insulin stimulation diminishes as plasma glucose falls toward normal levels.